Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3)

The summary for the Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3): The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The FOA will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.
Federal Grant Title: Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-16-065
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.242
CFDA Descriptions: Mental Health Research Grants
Current Application Deadline: Oct 24, 2018
Original Application Deadline: Oct 24, 2018
Posted Date: Dec 21, 2015
Creation Date: Dec 21, 2015
Archive Date: Nov 24, 2018
Total Program Funding:
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Special district governments
Small businesses
Native American tribal governments (Federally recognized)
For profit organizations other than small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
State governments
County governments
City or township governments
Public housing authorities/Indian housing authorities
Public and State controlled institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-16-065.html
Grant Announcement Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R...
Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R...
Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Ad...
Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021 FederalGrants.com